Dexamethason Sodium Phosphate Injection/Dexamethason Injection 4mg/1ml GMP Medicine

Product Details
Customization: Available
Application: Anti-Inflammatory
Usage Mode: Intravenous Injection
Still deciding? Get samples of US$ 0/box
Request Sample
Manufacturer/Factory, Trading Company

360° Virtual Tour

Diamond Member Since 2015

Suppliers with verified business licenses

Audited Supplier

Audited by an independent third-party inspection agency

Years of Export Experience
The export experience of the supplier is more than 10 years
High Repeat Buyers Choice
More than 50% of buyers repeatedly choose the supplier
Importers and Exporters
The supplier has import and export rights
Management Certification
The supplier has quality management system certification, including:
ISO9001:2015 certificate
ISO45001:2018 certificate
ISO14001
to see all verified strength labels (20)
  • Dexamethason Sodium Phosphate Injection/Dexamethason Injection 4mg/1ml GMP Medicine
  • Dexamethason Sodium Phosphate Injection/Dexamethason Injection 4mg/1ml GMP Medicine
  • Dexamethason Sodium Phosphate Injection/Dexamethason Injection 4mg/1ml GMP Medicine
  • Dexamethason Sodium Phosphate Injection/Dexamethason Injection 4mg/1ml GMP Medicine
  • Dexamethason Sodium Phosphate Injection/Dexamethason Injection 4mg/1ml GMP Medicine
  • Dexamethason Sodium Phosphate Injection/Dexamethason Injection 4mg/1ml GMP Medicine
Find Similar Products

Basic Info.

Model NO.
AMC14010-01
Suitable for
Elderly, Children, Adult
State
Liquid
Shape
Injection
Type
Organic Chemicals
Pharmaceutical Technology
Chemical Synthesis
Shelf Life
3 Years
Support OEM/ODM
Yes
Delivery Time
30 Days
Registration Documents
Available
Transport Package
10 Ampoules/Box
Specification
4mg/1ml
Trademark
Shinepharm
Origin
China
HS Code
3004909099
Production Capacity
1000000box/Month

Product Description

Product Description:

Each ampoule contains 4mg Dxms  phosphate,
Pharmacological Action:
Dxms  phosphate acts by controlling the rate of protein synthesis: It forms a steroid-receptor complex with receptor proteins, moves into the nucleus where it binds the chromatin and thus directs the genetic apparatus to transcribe RNA. It has a biological half-life in plasma of about 190 minutes and has relatively very weak sodium retaining properties.
Indications:
Conditions: where the anti inflammatory and immunosuppressive effects of a corticosteroid are desirable, including intensive treatment during shorter periods.
Contra-Indications:
Sensitive to corticosteroids, Tuberculosis, Ocular herpes simplex, Primary glaucoma. Acute psychosis and psychoneurosis, Systemic infection, Peptic ulcer, Osteoporosis.
Warning:
Dxms  phosphate Injection should not be administered intrathecally or subconjunctivally. Toxic effects may result from withdrawal or from continued use of large doses. Dxms  phosphate should be used with extreme caution in the presence of congestive heart failure, hypertension, in patients with diabetes mellitus, infectious diseases, chronic renal failure, uraemia and in elderly patients.
Dosage and indications for use.:
Usual adult dosage ranges from 0,5 to 20 mg daily depending on the severity of the disorder. Dxms phosphate may be administered intravenously or intramuscularly. The parenteral administration must be re
Dexamethason 
 
served for administration in emergencies or ad intensive therapy. Intra-articular, intralesional intra-muscular or soft-tissue injection: 0,8 to 4mg (depending on the size of the joint).
Side-effects:
Dxms  phosphate has little or no effect on sodium and water retention. Oedema, hypertension and an increased excretion of potassium with the possibility of hypokalaemic alkalosis may occur. Cardiac failure may be induced. Excessive metabolic effects may lead to mobilisation of calcium and phosphorous, with osteoporosis and spontaneous fractures, nitrogen depletion and hypergtycaemia with accentuation or precipitation of the diabetic state. The insullin requirements of diabetic patients are increased. Increased appetite is reported. The effect on tissue repair is manifest in delayed wound healing and increased susceptibility to all kinds of infection: including sepsis, fungal and viral infections have been reported, especially if patients are given antibiotics conjointly. Infections may also be masked. Acute adrenal insufficiency may occur during prolonged treatment or on cessation of treatment and may be precipitated by an infection or trauma. Growth retardation in children has been reported. Large doses may produce symptoms typical of hyperactivity of the adrenal cortex with moon-face sometimes with hirsutism, buffalo hump, flushing, increased bruising, striae, and acne, sometimes leading to fully developed Cushing's syndrome, Sudden cessation of administration is dangerous. Withdrawal should therefore always be gradual, the rate depending upon the individual patient's response, the dose, the disease being treated and the duration of therapy. Adrenal function should be monitored throughout withdrawal and symptoms attributable to over-rapid withdrawal should be countered by resuming a higher dose and continuing the reduction at a slower rate.
Storage:
Store below 25ºC. Protect from light. Keep out of reach of children. 
  
Production:
Dexamethason Sodium Phosphate Injection/Dexamethason Injection 4mg/1ml GMP Medicine

 

Inspection:
Dexamethason Sodium Phosphate Injection/Dexamethason Injection 4mg/1ml GMP Medicine
Loading:
Dexamethason Sodium Phosphate Injection/Dexamethason Injection 4mg/1ml GMP Medicine
Certificates:
Dexamethason Sodium Phosphate Injection/Dexamethason Injection 4mg/1ml GMP Medicine

  

 

Composition:

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now
Contact Supplier